Nicolas Glaichenhaus, CNRS/University Nice Sophia Antipolis, France
Nicolas Glaichenhaus, PhD, 57-year-old, is a Professor at the University Nice-Sophia Antipolis (UNS), and currently a team leader at the Molecular and Cellular Pharmacology Institute.
After obtaining his PhD in 1988, at the University Nice-Sophia Antipolis, he was appointed as a tenured researcher by the Centre National de la Recherche Scientifique (CNRS) and worked as a postdoctoral fellow that the University of California at Berkeley from 1988 to 1991. He returned to France in 1991 and was appointed Professor of Immunology at the University of Nice Sophia Antipolis and became team leader at the Molecular and Cellular Pharmacology Institute. For many years, Nicolas Glaichenhaus research efforts have been directed to investigate immune responses in mouse models of infectious diseases, autoimmunity or allergies. Five years ago, he has refocused his research to investigate how the brain and the immune system interact with each other. In this new field, he has already obtained several competitive research grants including one from the French Foundation for the Medical Research. Nicolas Glaichenhaus has contributed to more than 100 publications including several as first or senior author in prime scientific journals such as Science, Nature Medicine, Immunity, The Journal of Experimental Medicine and PlosPathogens.
Cytokine signatures and response to treatment in psychiatric disorders
Emanuela MARTINUZZI, PhD, CNRS, Université Nice Sophia Antipolis, Valbonne, France
Susana BARBOSA, PhD, CNRS, Université Nice Sophia Antipolis, Valbonne, France
Cyprien GILET, CNRS, Université Nice Sophia Antipolis, Valbonne, France
El Chérif IBRAHIM, PhD, CNRS, Aix-Marseille Université, Marseille, France
Raoul BELZEAUX, PhD, CNRS, Aix-Marseille Université, AP-HM, Marseille, France
Wafa BEL HAJ ALI, PhD, INSERM, Université Paris-Est Créteil, Créteil, France
Stéphane JAMAIN, PhD, INSERM, Université Paris-Est Créteil, Créteil, France
Professor Marion LEBOYER, INSERM, AP-HP, Créteil, France
Professor Nicolas GLAICHENHAUS, Université Nice Sophia Antipolis, Valbonne, France
Institut de Pharmacologie Moléculaire et Cellulaire
CNRS, Université de Nice-Sophia Antipolis
660 Route des Lucioles
Corresponding author: Nicolas GLAICHENHAUS (Nicolas.email@example.com)
Email addresses are provided for information in connection with the authors presentation only. Please do not mail credit card information under any circumstances.
Antidepressant and antipsychotic drugs are the mainstay of treatment for patients with major affective or psychotic disorders, ie, major depressive disorder, bipolar disorder, and schizophrenia. However, their effectiveness is highly variable due to disease heterogeneity and the lack of biological predictors of treatment response. Although treatment guidelines are available to assist clinicians in maximising therapeutic outcome and reducing side effects, the process of finding an effective pharmacotherapy is largely driven by trial and error, and remains challenging. This process can take several months until recovery is achieved. Furthermore, response rates to both antidepressant and antipsychotic medications are unsatisfactory, with only around a third of patients achieving complete remission. Preclinical and clinical studies have demonstrated a crucial role of the immune system in major affective and psychotic disorders. Based on these studies, we and others have hypothesised that immune-related serum biomarkers could be used as diagnostic and prognostic biomarkers in patients with psychiatric diseases. To validate this hypothesis, we have taken advantage of clinical data and serum samples that have been collected within two cohort studies of patients with either a psychotic or a major depressive episode, respectively. In these cohorts, we have analysed serum samples for 50 immune-related biomarkers and used advanced machine-learning methods to identify clinical and biological predictors of treatment response. In psychotic patients, we have identified several biomarkers that predicted response to treatment with an atypical antipsychotic as assessed by 10,000 iterations of 4-fold cross-validation. Further validation of our results in future clinical trials would pave the way for the development of a clinical-decision support system based on blood biomarkers to help diagnosis and prognosis in patients with major affective or psychotic disorders.
Funding: CNRS, grant from the Fondation de France
Conflicts of interest: None
« Go Back